Harpoon Therapeutics — Corporate Update (December 2022)
22 slides from Harpoon Therapeutics's corporate update, Dec 12, 2022
Slide 1: Spearheading Immunotherapies: ASH 2022 Review and Business Update
Spearheading Immunotherapies Ash 2022 review and business update December 12, 2022 Nasdaq: HARP Exhibit 99.2
Slide 2: Forward-looking statements
This presentation and accompanying oral commentary contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “target,” “estimate” and similar expressions (as well as other words or expre
Slide 3: Agenda
Agenda Introduction and Overview Julie Eastland Chief Executive Officer Review of HPN217 Interim Data Presented at ASH andLuke Walker, M.D. HPN328 Progress UpdateChief Medical Officer Summary and Q&AJulie Eastland
Slide 4: Clinical-Stage Immuno-Oncology Company Directing T Cells to Kill Tumors
Clinical-Stage Immuno-Oncology Company Directing T Cells to Kill Tumors Strong Capabilities Industry veterans developing novel TCEs Deep expertise in oncology, T cell engagement, and protein engineering Cash runway expected to fund operations through end of 2023 $66.1M in cash, cash equivalents & sh
Slide 5: Broad Pipeline of Immuno-Oncology Programs
Broad Pipeline of Immuno-Oncology Programs Clinical-Stage TriTAC® Programs, Novel TCE Platforms TriTAC/ProTriTAC Oncology TriTAC-XR Oncology / Non-Oncology Program Stage of Development Preclinical Phase 1 Phase 2 HPN2171 (BCMA) Multiple Myeloma HPN3282 (DLL3) Small Cell Lung Cancer / Other Solid Tum
Slide 6: HPN217 Targeting BCMA TriTAC Interim Data Presented at ASH 2022
HPN217 Targeting BCMA TriTAC® Interim Data Presented at ASH 2022
Slide 7: Multiple Myeloma: High Unmet Need Remains
Multiple Myeloma: High Unmet Need Remains Multiple Development Opportunities in a Rapidly Evolving Landscape 1 Over time period 2012 and 2018 Cancer stats Facts: Myeloma https://seer.cancer.gov/statfacts/html/mulmy.html BCMA means B-cell Maturation Antigen; RRMM means Relapsed/Refractory Multiple My
Slide 8: HPN217-3001 Phase 1/2 Trial Design
HPN217-3001 Phase 1/2 Trial Design Relapsed/Refractory Multiple Myeloma Dose Escalation 3+3 Design 0.005-1.62 mg 2.15 mg 2.86 mg 3.24* mg 6* mg 12* mg 24* mg Q1W (n=11) Q1W (n=17) Q1W (n=6) Q1W (n=7) Q1W (n=12) Q1W (n=3) Fixed- and Step-Dose Escalation Cohorts: 3-6 patients per dose level; Backfilli
Slide 9: HPN217: Study Patient Population Represents Real-World, Late-Line Population
HPN217: Study Patient Population Represents Real-World, Late-Line Population with High-Risk Features Baseline Characteristics Total N = 62 Age (yr), Median (range) Age > 75 years, n (%) 70 (38 – 83) 12 (19%) Time Since Initial MM Diagnosis (yr), Median (range) 8 (1 – 20) Baseline sBCMA (ng/mL), Medi
Slide 10: HPN217: Safety Summary
HPN217: Safety Summary Common Treatment-Emergent Adverse Events (Regardless of Relationship), >15% Note: Unaudited patient data are based on entries provided in open clinical database as of 10/17/2022 AE Preferred Term All Grades (N=62)a > Grade 3 (N=62)a Anemia 27 (44%) 21 (34%) Fatigue 20 (32%) 2
Slide 11: HPN217: ORR and CRS Rates Suggest Potentially Differentiated Profile
ASH 2021 CRS Current Data HPN217: ORR and CRS Rates Suggest Potentially Differentiated Profile with Widened Therapeutic Index *Note: Unaudited patient data based on entries provided in open clinical database as of 10/17/2022. Responses per Investigator Assessment (subject to change) 1Highest 2 dose
Slide 12: HPN217: Time on Treatment at Target Doses
HPN217: Time on Treatment at Target Doses > 2.15mg Deep Early Responses Observed at Highest Exposures Median overall responder time on treatment 7 months (range 1.6 - 18+) Early and Deep Responses across Highest Dose Levels Response Rate 77% (10/13) 6 of 7 responders from ASH ‘21 remain on tx for an
Slide 13: HPN217: Summary
HPN217: Summary 77% (10/13) ORR observed across highest step-dose levels (12 and 24 mg) Responses occurred early and were durable; for patients with at least 9 months follow up, the median responder time on treatment is 12 months 18 of 21 responders remain on study treatment with sustained response,
Slide 14: HPN328 Targeting DLL3 TriTAC
HPN328 Targeting DLL3 TriTAC®
Slide 15: Small Cell Lung Cancer Standard of Care
Small Cell Lung Cancer Standard of Care Limited effective options available in the relapsed/refractory setting 1 Atezolizumab and Durvalumab approved for 1L ES-SCLC in combination with platinum-doublet chemo and continued in maintenance for patients with ≥SD; 2 Lurbinectedin has accelerated approval
Slide 16: HPN328: Trial Design and Demographics
HPN328: Trial Design and Demographics A Phase 1/2 Open-Label, Multi-Center, Dose Escalation / Expansion, Safety & PK Study Target population SCLC relapsed after platinum chemotherapy Other high-grade neuroendocrine cancers R/R to standard of care (SOC) or no SOC available Trial objectives Assess saf
Slide 17: HPN328: Safety Summary
HPN328: Safety Summary Recent priming dose DLTs inform optimization of priming dose to support further escalation of target dose1 TriTAC platform designed to minimize CRS risk and allow for greater escalation of target dose, and re-escalation of target dose is underway No ICANS No DLTs at target dos
Slide 18: HPN328: Clinical Summary
HPN328: Clinical Summary Anti-tumor Activity Seen in Small Cell Lung Cancer at Higher Doses HPN328 is active; 71% SCLC patients had target tumor responses, including 1 confirmed partial response1, 2 25% (3/12) with >30% Target Lesion Shrinkage across all doses 1 Confirmed Partial Response – Durable
Slide 19: HPN328 Patient Case 1: Relapsed ES-SCLC
61-year-old female Diagnosed Jan 2021 with extensive-stage SCLC Location of metastases: TLs: lung, liver x2, lymph nodes x2 Non-TLs: lung x2, liver Prior systemic treatment: carboplatin + etoposide + atezolizumab Time on most recent prior systemic treatment: 20.1 weeks Upon study entry, stable disea
Slide 20: HPN328 Patient Case 2: Relapsed ES-SCLC
HPN328 Patient Case 2: Relapsed ES-SCLC 72% Reduction in Sum of Target Lesion Diameters Deepening of response over time continuing beyond ASCO 2022 data Data as of October 10, 2022 >99% decrease Durable >99% decrease in CTCs Baseline Week 9 On Treatment Response in peri-portal lymph node Patient His
Slide 21: HPN328: Anticipated Next Steps
HPN328: Anticipated Next Steps HPN328 is active Continue enrollment in the Phase 1 dose exploration study Monotherapy cohorts: 1 mg – 6 mg step dose cohort opened Optimization of priming dose for step-dosing regimens ongoing 27 patients planned to be enrolled by year end 2022 Start enrollment in Q2W
Slide 22: Summary and Anticipated Milestones
Summary and Anticipated Milestones Advancing pipeline of next-generation T cell engagers address broad patient populations with high unmet needs Strategic prioritization to focus resources on ongoing clinical programs in or nearing the clinic Clinically meaningful activity in hematology and solid tu
Harpoon Therapeutics — Corporate Update (December 2022) on 6ix